Stelmakh Edward's most recent trade in OptimizeRx Corp was a trade of 2,156 Common Stock done at an average price of $6.6 . Disclosure was reported to the exchange on Feb. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 15 Feb 2025 | 2,156 | 95,139 (0%) | 0% | 6.6 | 14,316 | Common Stock |
| OptimizeRx Corp | Stelmakh Edward | CFO/COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 77,742 | 77,742 | - | - | Stock Option | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 41,408 | 97,295 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Stelmakh Edward | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2024 | 5,237 | 10,474 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2024 | 5,237 | 38,603 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Stelmakh Edward | CFO/COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.75 per share. | 19 Dec 2024 | 1,316 | 37,287 (0%) | 0% | 4.8 | 6,251 | Common Stock |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 8,222 | 0 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 8,222 | 35,432 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.63 per share. | 11 Oct 2024 | 2,066 | 33,366 (0%) | 0% | 6.6 | 13,698 | Common Stock |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2024 | 16,622 | 16,583 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2024 | 16,622 | 31,387 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.83 per share. | 03 Oct 2024 | 4,177 | 27,210 (0%) | 0% | 7.8 | 32,706 | Common Stock |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 7,083 | 14,765 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2023 | 15,711 | 15,711 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2023 | 15,711 | 15,711 | - | - | Stock Option | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2023 | 8,221 | 28,034 (0%) | 0% | 0 | Common | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2023 | 16,662 | 21,344 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2023 | 16,662 | 33,205 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.06 per share. | 03 Oct 2023 | 4,117 | 17,227 (0%) | 0% | 7.1 | 29,066 | Common Stock |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2022 | 8,221 | 16,443 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2022 | 8,221 | 11,221 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2022 | 8,221 | 8,222 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2022 | 8,221 | 16,443 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2022 | 8,221 | 25,448 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.17 per share. | 11 Oct 2022 | 6,539 | 4,682 (0%) | 0% | 15.2 | 99,197 | Common Stock |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2022 | 6,155 | 31,603 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.17 per share. | 11 Oct 2022 | 3,539 | 7,682 (0%) | 0% | 15.2 | 53,687 | Common Stock |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.15 per share. | 11 Oct 2022 | 2,066 | 29,537 (0%) | 0% | 7.2 | 14,772 | Common Stock |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 97,637 | 97,637 | - | - | Stock Option | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 49,867 | 49,867 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Edward Stelmakh | CFO/COO | Purchase of securities on an exchange or from another person at price $ 15.43 per share. | 15 Aug 2022 | 3,000 | 3,000 (0%) | 0% | 15.4 | 46,290 | Common Stock |
| OptimizeRx Corp | Edward Stelmakh | COO and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2021 | 25,191 | 25,191 | - | - | Stock Option | |
| OptimizeRx Corp | Edward Stelmakh | COO and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2021 | 24,664 | 24,664 | - | - | Restricted Stock Units |